Catalyst Pharmaceuticals (CPRX) said Tuesday that its sub-licensee, DyDo Pharma, has launched Firdapse, or amifampridine, tablets 10 mg in Japan to treat muscle weakness in patients with Lambert-Eaton myasthenic syndrome, or LEMS, a rare autoimmune disorder.
Firdapse is the only treatment approved by the US Food and Drug Administration for LEMS in adults and pediatric patients aged six and older, and it is supported by a comprehensive patient support program in the US to ensure accessibility for eligible patients, the company said.
Shares of Catalyst Pharmaceuticals were down 1% in recent trading.
Price: 22.56, Change: -0.22, Percent Change: -0.97
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.